Development and clinical application of electroimmunoassays for the direct quantification of the complement C3 split products C3c and C3d

References

• Agnello V. Complement deficiency states. Medicine 1978; 57: 1–23
   PubMed Web of Science ®Google Scholar
• Bokisch V. A., Dierich M. P., Muller-Eberhard H. J. Third component of complement C3: Structural properties in relation to functions. Proc. Natl. Acad. Sci., USA 1975; 72: 1989–1993
   PubMedGoogle Scholar
• Brandslund I., Siersted H. C., Svehag S.-E., Teisner B. Double-decker rocket immunoelectrophoresis for direct quantitation of complement C3 split products with C3d specificities in plasma. J. Immunol. Methods 1981; 44: 63–71
   PubMed Web of Science ®Google Scholar
• Brandslund I., Teisner B., Svehag S.-E. Direct quantitation of the complement C3 split product C3d in immunopathological disorders. Marker Proteins in Inflamation, Bienvenu Allen. Laurent and Suskind, De Gruyter, Berlin 1982; 424–426
   Google Scholar
• Brandslund I., Petersen Hyltoft P., Teisner B., Rasmussen G. G. Comparison of different methods for determination of the complement split product C3d. Ann. Biol. Clin. 1982; 40: 428
   Google Scholar
• Brandslund I., Teisner B., Hole P., Grudzinskas J. G., Svehag S.-E. Complement activation in shock associated with a surgically provoked bacteriaemia. Acta pathol. microbiol. Immunol. Scand. sect. C. 1983; 92: 51–57
   Google Scholar
• Brandslund I., Svehag S.-E., Teisner B., Petersen P. H. Activation of the complement system and accumulation of haemoglobin-haptoglobin complexes in plasma during an adverse reaction to penicillin treatment. Int. Arch. Allergy and Appl. Immunol. 1983; 72: 137–143
   Google Scholar
• Brandslund I., Teisner B., Strate M., Grunnet N., Svehag S.-E., Isager H., Wang P. The normal occurrence of two molecular forms of the eight complement component and their concentrations in a family with C8 deficiency. Eur. J. Clin. Invest. 1983; 13: 179–182
   PubMedGoogle Scholar
• Brandslund I., Peters N. D., Ejstrup L., Teisner B., Rasmussen G. G. Steroids and complement activation in rheumatoid arthritis. Lancet 1983; II: 8345, 346–347
   Google Scholar
• Brown D. L. Complement activation profiles in disease. J. Clin. Path. 1979; 32(Suppl. 13)116–119, (Ed. E.J. Holborow)
   Google Scholar
• Brown E. J., Frank M. M. Complement activation. Immunology today 1981; 2: 129–134
   PubMedGoogle Scholar
• Charlesworth J. A., Williams Gwyn D., Sherington E., Lachmann P. J., Peters D. K. Metabolic studies of the third component of complement in patients with hypocomplementemia. J. Clin. Invest. 1974; 53: 1578–1587
   PubMed Web of Science ®Google Scholar
• Fearon D. T., Austen K. F. The alternative pathway of complement-a system for host resistance to microbial infection. N. Engl. J. Med. 1980; 303: 259–263
   PubMed Web of Science ®Google Scholar
• Gewurz A. T., Lint T. F., Imherr S. M., Garber S. S., Gewurz H. Detection and analysis of inborn and acquired complement abnormalities. Clin. Immunol. and Immunopathol. 1982; 23: 297–311
   PubMedGoogle Scholar
• Hüttel M. S., Olesen M. S., Stoffersen E. Complement-mediated reactions to Diazepam with cremophor as solvent. Br. J. Anaesth. 1980; 52: 77–79
   PubMed Web of Science ®Google Scholar
• Kazatchkine M. D., Nydegger U. E. The human alternative complement pathway: Biology and immunopathology of activation and regulation. Prog. Allergy 1982; 30: 193–234, Karger, Basel
   PubMedGoogle Scholar
• Lachmann P. J. Association of immune complex disease with complement deficiency. Immunopathol. 6th Int. convoc. Immunol. Niagara Falls, N.Y. 1978; 274–279, Karger, Basel, 1979
   Google Scholar
• Lachmann P. J. Studies with monoclonal antibodies to complement components. Immunol. today 1981; 2: 144
   PubMedGoogle Scholar
• Loos M. The classical complement pathway: Mechanism of activation of the first component by antigen-antibody complexes. Prog. Allergy 1982; 30: 135–192, Karger, Basel
   PubMedGoogle Scholar
• Müller-Eberhard H. J. Complement abnormalities in human disease. Hospital practice 1978; 13: 65–76
   PubMed Web of Science ®Google Scholar
• Perrin L. H., Lambert P. H., Miescher P. A. Complement breakdown products in plasma from patients with membranoproliferative or other glomerulonephritis. J. Clin. Invest. 1975; 56: 165–176
   PubMed Web of Science ®Google Scholar
• Porter R. R., Reid K. B.M. Activation of the complement system by antibody-antigen complexes: the classical pathway. Advances in pratein chemistry, C. B. Anfinsen, F. M. Edsall, Richards. Academic Press, NY 1979; vol. 33: 1–71
   Google Scholar
• Rasmussen G. G., Brandslund I., Urfe P., Teisner B., Siersted H. C., Hindersson P., Lund H. I., Nielsen E. F., Arfelt E., Jensen A., Dalsgaard J., Svehag S.-E., Dyerberg J., Nymand G. No effect of tranexamic acid (cyklocapronR) on rheumatoid arthritis. Submitted to Scand. J. Rheumatology 1980; 28/6: 2983, In press
   Google Scholar
• Rother K. Biological functions of the complement system. Monogr. Allergy 1977; 22: 90–100, Karger, Basel
   Google Scholar
• Sinosich M., Teisner B., Brandslund I., Fischer M., Grudzinskas J. G. The influence of coagulation, time and temperature on the measurement of C3 split products and C4. J. Immunol. Methods 1982; 55: 127–114
   Google Scholar
• Sørensen H., Dissing J. Association between the C3F gene and atherosclerotic vascular disease. Hum. Hered. 1975; 25: 279
   PubMed Web of Science ®Google Scholar
• Tappeiner G. Disease states in genetic complement deficiencies. Int. J. Dermatol. 1982; 21: 175–191
   PubMed Web of Science ®Google Scholar
• Teisberg P. In vivo activation of C3 revealed by crossed immunoelectrophoresis as a parameter of immunological activity in disease. Clin. Chim. Acta 1975; 62: 35–41
   PubMed Web of Science ®Google Scholar
• Teisner B., Brandslund I., Hau J., Svehag S.-E. Heterogeneity in electrophoretic mobility of C3-derived molecules expressing D, but not C-epitopes following in vivo activation of the complement system. Acta pathol. microbiol. immunol. Scand. sect. C 1983; 91: 85–87
   PubMedGoogle Scholar
• Teisner B., Brandslund I., Grunnet N., Hansen L. K., Thellesen J., Svehag S.-E. Acute complement activation during an anaphylactoid reaction to blood transfusion and the disappearance rate of C3d and C3c from the circulation. J. Clin. Lab. Immunol. 1983; 12: 63–67
   PubMedGoogle Scholar
• Teisner B., Hau J., Svehag S.-E., Brandslund I., Bøg-Hansen T. C. The third complement factor (C3) and its in vivo cleavage products: Interaction with lectins and precipitation with polyethylene glycol. Accepted J. Immunol. Meth. September, 1983
   Google Scholar
• De Vecchi A., Montaguino G., Massaro L., Constantino A., Bencini P. L., Tarantino A. Comparison between immunofixation and crossed immuno-electrophoresis for the detection of C3 activation products. Clin. Chim. Ada 1979; 97: 27–31
   PubMedGoogle Scholar
• Watkins J. Anaphylactoid reactions to intravenous substances. BY. J. Anaesth. 1979; 51: 51–60
   PubMedGoogle Scholar
• Whicher J. T. The value of complement assays in clinical chemistry. Clin. Chem. 1978; 24: 7–22
   PubMedGoogle Scholar